<DOC>
	<DOCNO>NCT01804244</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics safety TMC278 single oral dose TMC278 25 mg tablet ( 27.5 mg hydrochloride salt ) feed condition healthy Japanese adult male participant .</brief_summary>
	<brief_title>A Single-Dose Pharmacokinetics Safety Study TMC278 Healthy Adult Japanese Participants</brief_title>
	<detailed_description>This single center , open-label ( study staff participant know identity treatment assign ) , single dose study healthy Japanese adult male participant . The study consist 3 phase : screen phase 26 day ; inpatient phase Day -2 Day 8 ; follow-up assessment phase occur Day 15 ( ± 2 day ) time participant 's early withdrawal study . Participants meet selection criterion admit investigational institute two day dose ( Day -2 ) . All enrol participant receive orally ( mouth ) single dose one TMC278 25 mg tablet Day 1 within 10 minute completion standardize breakfast . Enrolled participant remain investigational institute entire duration inpatient phase . Participants discharge Day 8 completion require assessment . Blood sample determination plasma concentration TMC278 collect period 168 hour ( 7 day ) . The maximum study duration participant 45 day , include screen phase , in-patient period , follow-up visit .</detailed_description>
	<mesh_term>Rilpivirine</mesh_term>
	<criteria>Japanese healthy men body mass index ( BMI ) 18.5 25.0 kg/m² , inclusive body weight less 50 kg History current medical illness consider investigator clinically significant exclude participant could interfere interpretation study result Laboratory abnormality grade 2 great ( define World Health Organization Adult Toxicity Table ) clinically significant abnormal value assess investigator Clinically significant abnormal physical examination vital sign screen assessed investigator Use prescription nonprescription medication ( include vitamin herbal supplement ) , within 14 day dose TMC278 25 mg tablet History clinically significant drug food allergy , especially know hypersensitivity and/or know allergy TMC278 excipients formulation</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Japanese</keyword>
</DOC>